ArticleCancers2022

Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study.

Valerio Gristina et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.